Clinical trial
An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome
NCT02599961 is registered in ClinicalTrials.gov with Ultragenyx Pharmaceutical Inc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- An Open-label Extension Study to Assess the Long-term Safety and Efficacy of UX007 in Subjects With Glucose Transporter Type 1 Deficiency Syndrome
- Lead sponsor
- Ultragenyx Pharmaceutical Inc
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- September 10, 2015
- Completion date
- October 22, 2019
- Enrollment
- 15 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.
glucose transporter type 1 deficiency syndrome